May 25th, 2019

BioVersys Receives QIDP Designation from the U.S. FDA for the Development of BV100

BioVersys to develop BV100 in critical care indications

BioVersys AG a privately owned, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation, announced today that its preclinical candidate BV100 has received Qualified Infectious Disease Product designation from the U.S. FDA for intravenous use in the treatment of ventilator-associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP) and bloodstream infections (BSI).

Our Press Release is here